Article:
Chordoma: Prognostic Factors
- Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Naka, T., Boltze, C., Samii, A., Herold, C., Ostertag, H., Iwamoto, Y., Oda, Y., Tsuneyoshi, M., Kuester, D., Roessner, A. Cancer. (2003)
- Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Noël, G., Feuvret, L., Calugaru, V., Dhermain, F., Mammar, H., Haie-Méder, C., Ponvert, D., Hasboun, D., Ferrand, R., Nauraye, C., Boisserie, G., Beaudré, A., Gaboriaud, G., Mazal, A., Habrand, J.L., Mazeron, J.J. Acta. Oncol. (2005)
- Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. Holton, J.L., Steel, T., Luxsuwong, M., Crockard, H.A., Revesz, T. Neuropathol. Appl. Neurobiol. (2000)
- Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Mitchell, A., Scheithauer, B.W., Unni, K.K., Forsyth, P.J., Wold, L.E., McGivney, D.J. Cancer. (1993)
- Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas?. Yamaguchi, T., Suzuki, S., Ishiiwa, H., Ueda, Y. Histopathology. (2004)
- First histologically confirmed case of a classic chordoma arising in a precursor benign notochordal lesion: differential diagnosis of benign and malignant notochordal lesions. Yamaguchi, T., Yamato, M., Saotome, K. Skeletal. Radiol. (2002)
- Differential proteomic profiling of chordomas and analysis of prognostic factors. Zhou, H., Chen, C.B., Lan, J., Liu, C., Liu, X.G., Jiang, L., Wei, F., Ma, Q.J., Dang, G.T., Liu, Z.J. J. Surg. Oncol. (2010)
- Surgical margins and local control in resection of sacral chordomas. Ruggieri, P., Angelini, A., Ussia, G., Montalti, M., Mercuri, M. Clin. Orthop. Relat. Res. (2010)
- Chordoma of the skull base: predictors of tumor recurrence. Pallini, R., Maira, G., Pierconti, F., Falchetti, M.L., Alvino, E., Cimino-Reale, G., Fernandez, E., D'Ambrosio, E., Larocca, L.M. J. Neurosurg. (2003)
- Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas. Saad, A.G., Collins, M.H. Pediatr. Dev. Pathol. (2005)
- The role of chemotherapy in pediatric clival chordomas. Dhall, G., Traverso, M., Finlay, J.L., Shane, L., Gonzalez-Gomez, I., Jubran, R. J. Neurooncol. (2010)
- Impact of cytogenetic abnormalities on the management of skull base chordomas. Almefty, K.K., Pravdenkova, S., Sawyer, J., Al-Mefty, O. J. Neurosurg. (2009)
- Steroid hormone receptor and COX-2 expression in chordoma. Fasig, J.H., Dupont, W.D., Olson, S.J., Lafleur, B.J., Cates, J.M. Am. J. Clin. Pathol. (2007)
- Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Naka, T., Boltze, C., Kuester, D., Schulz, T.O., Schneider-Stock, R., Kellner, A., Samii, A., Herold, C., Ostertag, H., Roessner, A. Cancer. (2005)
- Cadherins and catenins in clival chordomas: correlation of expression with tumor aggressiveness. Triana, A., Sen, C., Wolfe, D., Hazan, R. Am. J. Surg. Pathol. (2005)
- Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Rahmah, N.N., Sakai, K., Nakayama, J., Hongo, K. Neurosurg. Rev. (2010)
- Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Naka, T., Kuester, D., Boltze, C., Schulz, T.O., Samii, A., Herold, C., Ostertag, H., Roessner, A. Hum. Pathol. (2008)
- Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis. Sakai, K., Hongo, K., Tanaka, Y., Nakayama, J. Brain. Tumor. Pathol. (2007)
- Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Yang, H., Zhu, L., Ebraheim, N.A., Liu, X., Castillo, S., Tang, T., Liu, J., Cui, H. Spine. J. (2009)
- Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. Presneau, N., Shalaby, A., Ye, H., Pillay, N., Halai, D., Idowu, B., Tirabosco, R., Whitwell, D., Jacques, T.S., Kindblom, L.G., Brüderlein, S., Möller, P., Leithner, A., Liegl, B., Amary, F.M., Athanasou, N.N., Hogendoorn, P.C., Mertens, F., Szuhai, K., Flanagan, A.M. J. Pathol. (2011)
- A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Yang, C., Schwab, J.H., Schoenfeld, A.J., Hornicek, F.J., Wood, K.B., Nielsen, G.P., Choy, E., Mankin, H., Duan, Z. Mol. Cancer. Ther. (2009)
- Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Fasig, J.H., Dupont, W.D., LaFleur, B.J., Olson, S.J., Cates, J.M. Neuropathol. Appl. Neurobiol. (2008)
- Expression of hepatocyte growth factor and c-MET in skull base chordoma. Naka, T., Kuester, D., Boltze, C., Scheil-Bertram, S., Samii, A., Herold, C., Ostertag, H., Krueger, S., Roessner, A. Cancer. (2008)